The level of antibody against E6 HPV 16 oncoprotein in blood sera of women with chronic HPV 16 infection and cervical cancer

The aim of this study was to estimate of the role of chronic HPV 16 infection and the presence of anti E6 HPV 16 in the initiation of the cancerogenesis process of cervical cancer.

Material and methods: The study included two groups of patients. The first group comprised 323 women observed for three consecutive years (1998-2000), in whom the presence of HPV 16 viruses was estimated by PCR, and the level of anti E6 HPV 16 antibodies was estimated in the plasma with ELISA. A similar test was performed in a group of 46 patients with cervical intraepithelial neoplasia (CIN), 91 patients with invasive cervical cancer and 22 women after hysterectomy and RTG-therapy.

Results: In 32 patients, chronic HPV 16 infection showed a steady rise in the mean absorbance level of anti E6 HPV 16 antibodies from 0.04 in 1998 to 0.06 in 2000, while in HPV-negative women the mean absorbance value was 0.03-0.04. Mean absorbance value in patients with CIN III and invasive cancer rose with advancing stage of the cancer process and lowered after completion of oncological treatment. The values were 0.14, 0.33 and 0.13, respectively.

Conclusion: The persistence of chronic HPV 16 infection and accompanying steady rise in absorbance index caused by an increase in the level of antiviral antibodies are a clear warning signal preceding in time the histological process of cancerogenesis.

Cervical cancer; HPV 16; Chronic infection; Antibody

[1] Auvinen E., Crusius K., Steuer B., Alonso A.: "Human papillomavirus type 16 ES-protein ( review)". Int. J. Oneal., 1997, 11, 1297.

[2] Baay M.F., Duk J.M., Groenier K.H., Burger M.P., de Bruijn H.W., Hollema H. et al.: "Relation between HPV-16 serology and clinico-pathological data in cervical carcinoma patients: prognostic value of anti-E6 and/or anti-E7 antibodies". Cancer Immunol lmmunother., 1997, 44, 211.

[3] Burd E.M.: "Human papillomavirus and cervical cancer". Clin. Microbial Rev., 2003, 16, 1.

[4] Carter J.J., Galloway D.A.: "Humoral immune response to human papillomavirus infection". Clin. Dermatol., 1997, 15, 249.

[5] Chee Y.H., Namkoong S.E., Kim D.H., Kim S.J., Park J.S.: "Immunologic diagnosis and monitoring of cervical cancers using in vitro translated HPV proteins". Gynecol. Oneal., 1995, 57, 226.

[6] Chellappan S., Kraus V.B., Kroger B., Munger K., Howley P.M., Phelps W.C., Nevins J.R.: "Adenovirus ElA, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product". Proc. Natl. Acad. Sci. USA, 1992, 89, 4549.

[7] Daniels P.R., Sanders C.M., Maitland N.J.: "Characterization of the interactions of human papillomavirus type 16 E6 with p53 and E6-associated protein in insect and human cells". J. Gen. Viral., 1998, 79, 489.

[8] De Sanjose S., Hamsikova E., Munoz N., Bosch F.X., Hofmannova V., Gili M. et al.: "Serological response to HPV 16 in CIN III and cervical cancer patients. Case-control studies in Spain and Colombia". Int. J. Cancer, 1996, 66, 70.

[9] Dillner J., Kallings I., Brihmer C., Sikstrom B., Koskela P., Lehtinen M. et al.: "Seropositivities to human papillomavirus types 16, 18, or er 33 capsid and and to Chlamydia trachomatis are markers of sexual behavior". J. Infect. Dis., 1996, 173, 1394.

[10] Dillner J., Lehtinen M., Bjorge T., Luostarinen T., Youngman L., Jellum E. et al.: "Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer". J. Natl. Cancer Inst., 1997, 89, 1293.

[11] Dillner J., Lenner P., Lehtinen M., Eklund C., Heino P., Wiklund F., Hallmans G., Stendahl U.: "A population-based seroepidemiological study of cervical cancer". Cancer Res., 1994, 54, 134.

[12] Dillner J., Wiklund F., Lenner P., Eklund C., F rederikssonShanazarian V., Schiller J. et al.: "Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer". Int. J. Cancer, 1995, 60, 377.

[13] Dyson N., Howley P.M., Munger K., Harlow E.: "T he human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product". Science, 1989, 243, 934.

[14] Fife K.H., Rogers R.E., Zwickl B.W.: "Symptomatic and asymptomatic cervical infections with human papillomavirus during pregnancy". J. Infect. Dis., 1987, 156, 904.

[15] Fisher S.G., Benitez-Bribiesca L., Nindl I., Stockfleth E., Muller M., Perez-Garcia F et al.: "T he association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer". Gynecol. Oncol., 1996, 61, 73.

[16] Hamsikova E., Novak J., Hofmannova V., Munoz N., Bosch F.X., de Sanjose S., Shah K., Roth Z., Vonka V.: "Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls". J. Infect. Dis., 1994, 170, 1424.

[17] Hamsikova E., Smahel M., Sapp M., Munoz N., Bosch F.X., Shah K.V., Vonka V.: "Correlation between the presence of anti HPV33 V LP antibodies and HPV DNA in cervical neoplasia patients". Arch. Viral., 1997, 142, 413.

[18] Lehtinen M., DiIIner J., Knekt P., Luostarinen T., Aromaa A.，Kirnbauer R., Koskela P., Paavonen J., Peto R., Schiller J., Hakama M "Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study". Br. Med. J., 1996, 312, 537.

[19] Mann V.M., de Lao S.L., Brenes M., Brinton L.A., Rawls J.A., Green M. et al.: "Occurrence of lgA and IgG antibodies to select peptides representing human papillomavirus type 16 among cervical cancer cases and controls". Cancer Res., 1990, 50, 7815.

[20] Muller M., Viscidi R.P., Sun Y., Guerrero E., Hill P.M., Shah F. et al.: "Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer". Virology, 1992, 187, 508.

[21] Nonnenmacher B., Hubbert N.L., Kimbauer R., Shah K.V., Munoz N., Bosch F.X. et al.: "Serologic response to human papillomavirus type 16 (HPY-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain". J. Infect. Dis., 1995, 172, 19.

[22] Olsen A.O., Dillner J., Gjoen K., Sauer T., Orstavik I., Magnus P "A population-based case-control study of human papillomavirus type 16 seropositivisy and incident hjgh:srade dysplasia of the uterine cervix". Int. J. Cancer, 1996, 15, 415.

[23] Pim D., Collins M., Banks L.: "Human pap仆lomavirus type 16 ES gene stimulates the transforming activity of the epidermal growth factor receptor". Oncogene, 1992, 7, 27.

[24] Scheffner M., Wemess B.A., Huibregtse J.M., Levine A.J., Howley P.M.: "The E6 oncoprotein encoded by human papillomavirus types16 and 18 promotes the degradation of p53". Cell, 1990, 63, 1129

[25] Schmidt M., K凶zia W., Goidzicka-J6zefiak A.: "Intratype HPV 16 sequence variation within LCR of isolates from asymptomatic carriers and cervical cancers". J. Clin. Virol., 2001, 23, 65.

[26] Sethi S., Muller M., Schneider A., Blettner M., Smith E., Turek L et al.: "Serologic response to the E4, E6, and E7 proteins of human papillomavirus type 16 in pregnant women". Am. J. Obstet. Gynecol., 1998, 178, 360.

[27] Strickler H.O., Schiffman M.H., Eklund C., Glass A.G., Scott D.R., Sherman M.E. et al.: "Evidence for at least two distinct groups of humoral lmmune reactions to papdlomawrus anugens m women with squamous intraepithelial lesions". Cancer Epidemiol. Biomarkers Prev., 1997, 6, 183.

[28] Suchankova A., Ritterova L., Krcmar M., Krchnak V., Vagner J., Jochmus I. et al.: "Comparison of ELISA and western blotting for human papillomavirus type 16 E7 antibody determination". J Gen. Virol., 1991, 72, 2577.

[29] Sun Y., Shah K., Muller M., Munoz N., Bosch F.X., Viscidi R.P "Comparison of peptide enzyme-linked immunosorbent assay and radioimmunoprecipitation assay with in vitro-translated proteins for detection of serum antibodies to human papillomavirus type 16 E6 and E7 proteins". J. Clin. Microbiol., 1994, 32, 2216.

[30] Syrjanen K., Nurmi T., Manly」arvi R., Ilonen J., Syrjanen S., Surcel H.M., Y liskoski M., Vayrynen M., Chang F., Saarikoski S.: "HLA types in women with cervical human pap仆lomavirus (HPV ) lesions prospectively followed up for 10 years". Cytopathology, 1996, 7, 99.

[31] Syrjanen K., Syrjanen S.M.: "Papillomavirus Infections in Human Pathology". Chichester: Wiley, 2000.

[32] Syrjanen K., Vayrynen M., Castren 0., Mantyjarvi R., Y liskosk1 M.: "The relation between the type of immunoreactive cells found in human papillomavirus (HPV) lesions of the uterine cervix and the subsequent behaviour of these lesions". Arch. Gynecol., 1984, 234, 189.

[33] Viladiu P., Bosch F.X., Castellsague X., Munoz N., Escriba J.M., Hamsikova E et al.: "Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer". J. Clin. Oncol., 1997, 15, 610.

[34] Wideroff L., Schiffman M.H., Nonnenmacher B., Hubbert N., Kirnbauer R., Greer C.E. et al.: "Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia". J. Infect. Dis., 1995, 172, 1425.

[35] Zehbe I., Wilander E., Delius H., Tommasino M.: "Human papilloma 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype". Cancer Res., 1998, 58, 829.